selected scholarly activity
-
chapters
- Bacterial contamination in blood and blood components. 87-116. 2008
- Transfusion-Related Acute Lung Injury. 691-700. 2007
-
conferences
- Randomized Trial Results: Red Cell Storage Age is Not Associated with a Significant Difference in Multiple-Organ Dysfunction Score or Mortality in Transfused Cardiac Surgery Patients. Transfusion. 15A-15A. 2014
- Scientific Section. Transfusion. 11A-284A. 2012
- Protecting the blood supply from emerging pathogens: The role of pathogen inactivation. Transfusion Clinique et Biologique. 70-74. 2009
- Results of Anti-HBc screening of blood donors at Canadian blood services - One year of testing. Transfusion. 22A-22A. 2006
- A multicenter, randomized, controlled clinical pilot trial of the feasibility of an intensive RBC transfusion policy for patients with acute leukemia treated with induction chemotherapy or stem cell transplant.. Blood. 126B-126B. 2005
- Proceedings of a Consensus Conference: Towards an Understanding of TRALI. Transfusion Medicine Reviews. 2-31. 2005
- The Mechanism of Transfusion-Related Immunomodulation Is Related to the Transfusion of Dendritic Cells Expressing the CD200 (OX-2) Tolerance Signal and Alloantigen: Evidence from a Murine Tumor Model.. Blood. 831-831. 2004
- The Use of Aprotinin to Reduce Transfusion Requirements in Children Undergoing Cardiac Surgery: A Meta-Analysis.. Blood. 2718-2718. 2004
- 270 A Randomized Controlled Trial of Low vs High Hemoglobin Thresholds for Transfusion in Extremely Low-Birth-Weight Infants. Pediatric Research. 510-510. 2004
- A randomized crossover trial comparing in-vivo platelet recovery and survival of leukoreduced apheresis and whole blood derived platelets. Transfusion. 1A-1A. 2004
- Identifying the optimal red cell transfusion threshold for extremely low birth weight infants: The premature in need of transfusion (PINT) study. Transfusion. 1A-1A. 2004
- Premature infants in need of transfusion - The PINT study. A multicentre international randomized controlled trial (RCT) of blood transfusion in ELBW infants. Pediatric Research. 463A-463A. 2004
- Auditing of hospital armband identification practices in four acute care hospitals. Transfusion. 171A-171A. 2003
- Pilot study comparing the medical event reporting system-transfusion medicine to an in-house event reporting system for a multi-site transfusion service. Transfusion. 163A-163A. 2003
- Severe hypotension following transfusion of pre-storage leukoreduced red blood cells and acute normovolemic hemodilution whole blood. Transfusion. 112A-112A. 2003
- The detection of anti-Jkb in a JK1/JKd6 transfusion recipient. Transfusion. 24S-24S. 2001
- Comparison of post transfusion platelet response following random donor and apheresis platelets.. Blood. 62A-62A. 2000
- Hyperbilirubinemia secondary to gamma-irradiation of red cells.. Blood. 111B-111B. 2000
- Comparison of post transfusion platelet response following random donor and apheresis platelets. Transfusion. 45S-45S. 2000
- A randomized trial comparing plasma removal to two types of pre-storage leukoreduction to prevent reactions to platelets.. Blood. 376A-376A. 1999
- Platelet substitutes. Blood. 77-77. 1999
- A randomized trial comparing plasma removal to two types of pre-storage leukoreduction to prevent reactions to platelets. Transfusion. 96S-97S. 1999
- Calcium dependency of conformational changes in the EGF-1 region upon activation, but not active site inhibition, of human FVII. Thrombosis and Haemostasis. 466-466. 1999
- Both activation and active site occupation of human factor VII alter conformation of the first EGF-life domain.. Blood. 41A-41A. 1998
- Relative flux of hemostatic proteins to a de novo site of vascular injury in vivo.. The FASEB Journal. A955-A955. 1998
- Expression and purification of recombinant rabbit factor VII. The FASEB Journal. A190-A190. 1998
- Fibrinogen, prothrombin and antithrombin uptake in vivo by malignant VX-2 lung tumor nodules in rabbits.. The FASEB Journal. A475-A475. 1998
- Exposure in vivo of rabbit platelets to thrombospheres augments the ADP-induced decrease in platelet phosphatidylinositol 4,5-bisphosphate (PIP2) ex vivo.. Blood. 2998-2998. 1997
- Reduction by in-line leukocyte filtration of bacterial contaminants is more effective after an 8 hour hold at 22C than at 4C.. Transfusion. S45-S45. 1997
- Binding of thrombospheres to chymotrypsin-treated rabbit platelets decreases phosphatidylinositol 4,5-bisphosphate (PIP2). Thrombosis and Haemostasis. P1964-P1964. 1997
- Misfolding of the first epidermal growth factor domain results in decreased cellular secretion of factor VII. Thrombosis and Haemostasis. P1651-P1651. 1997
- Mutability of reactive centre loop P4 and P5 residues in human and rabbit antithrombin. Thrombosis and Haemostasis. P1427-P1427. 1997
- Thrombin-antithrombin (TAT) complexes interact with cytokeratin 18 from rabbit hepatocytes. Thrombosis and Haemostasis. P1431-P1431. 1997
- A novel and de novo spontaneous point mutation (GLU270STOP) of the antithrombin (AT) gene results in a type I deficiency and congenital thrombophilia.. Blood. 680-680. 1996
- Bacterial surveillance of platelet concentrates: A comparison of day 1 versus day 3 bacterial cultures.. Blood. 1134-1134. 1996
- Development of a pilot scale protocol for the preparation of lyophilized human platelets that retain physiological integrity and hemostatic functionality.. Blood. 1406-1406. 1995
- Development of an elastase-resistant antithrombin through mutagenesis at P4.. Blood. 1416-1416. 1995
- Evidence for in vivo thrombin generation following the transfusion of blood from a post-operative drainage device.. Blood. 2159-2159. 1995
- Red cell transfusion practice in the intensive care unit: A systematic evaluation.. Blood. 3416-3416. 1995
- Thrombin-antithrombin (TAT) complexes interact with cytokeratin 18 (CK18) on the surface of hepatocytes.. Blood. 1417-1417. 1995
- CIRCULATORY SURVIVAL OF RECOMBINANT RABBIT ANTITHROMBIN AND DEGLYCOSYLATION MUTANTS. Thrombosis and Haemostasis. 1249-1249. 1995
- DELETION MUTAGENESIS OF HEPARIN COFACTOR-II - DEFINING THE MINIMAL FUNCTIONAL DOMAINS OF A PLASMA THROMBIN INHIBITOR. Thrombosis and Haemostasis. 945-945. 1995
- INTRACELLULAR EVENTS DETERMINE THE FATE OF ANTITHROMBIN UTAH. Thrombosis and Haemostasis. 935-935. 1995
- HEPATITIS NON-ABC - IS THERE YET ANOTHER POST TRANSFUSION HEPATITIS (PTH). Gastroenterology. A1064-A1064. 1995
- THE HEMOSTATIC RESPONSE TO ARTERIAL INJURY INVIVO - BEHAVIOR OF PROTHROMBIN AT THE DE-ENDOTHELIALISED AORTA WALL. CARDIOVASCULAR DISEASE 2. 279-289. 1995
- HEMOSTATIC PROPERTIES OF HUMAN LYOPHILIZED PLATELETS IN A THROMBOCYTOPENIC RABBIT MODEL AND A SIMULATED BLEEDING-TIME DEVICE. Blood. A464-A464. 1994
- TRINUCLEOTIDE REPEAT POLYMORPHISM IN THE ANTITHROMBIN-III GENE - ALLELE FREQUENCY DATA FOR 3 POPULATION GROUPS. American Journal of Human Genetics. 1647-1647. 1993
- CHARACTERIZATION OF A HIGHLY POLYMORPHIC TRINUCLEOTIDE SHORT TANDEM REPEAT (STR) WITHIN THE HUMAN ANTITHROMBIN (AT) GENE ON CHROMOSOME-1 - LINKAGE WITH THE AT-HAMILTON ALLELE. Thrombosis and Haemostasis. 751-751. 1993
- CHARACTERIZATION OF A PUTATIVE 45-KDA RABBIT HEPATIC RECEPTOR FOR THROMBIN-ANTITHROMBIN-III (TAT) COMPLEXES. Thrombosis and Haemostasis. 1141-1141. 1993
- EVIDENCE FOR HEPARIN COFACTOR-II (HCII) AS A PHYSIOLOGICAL INHIBITOR OF THROMBIN. Thrombosis and Haemostasis. 899-899. 1993
- FACTOR-VII HAMILTON - A NOVEL TYPE-2 MUTATION LOCATED AT RESIDUE-57 IN THE 1ST EGF DOMAIN OF HUMAN FACTOR-VII. Thrombosis and Haemostasis. 1291-1291. 1993
- INACTIVATION OF FACTOR-VIIIA BY FACTOR-XA. Thrombosis and Haemostasis. 1087-1087. 1993
- INACTIVATION OF FACTOR-VIIIA BY THROMBIN. Thrombosis and Haemostasis. 1087-1087. 1993
- SITE-DIRECTED MUTAGENESIS OF HUMAN ANTITHROMBIN RESIDUE-392 (P2) REVEALS A VARIANT WITH ENHANCED BIOLOGICAL-ACTIVITY. Thrombosis and Haemostasis. 1140-1140. 1993
- THE INTERACTION OF THROMBIN-ANTITHROMBIN-III (TAT) COMPLEXES WITH HEPG2 CELLS UP-REGULATES ANTITHROMBIN-III PRODUCTION. Thrombosis and Haemostasis. 760-760. 1993
- USE OF ANTITHROMBIN RECOMBINANT DERIVATIVES AND FUSION PRODUCTS TO MAP ITS HEPARIN-BINDING DOMAINS. Thrombosis and Haemostasis. 1140-1140. 1993
- FACTOR-VII CHARLOTTE - A DYSFUNCTIONAL F-VII WITH A MUTATION IN THE 1ST EPIDERMAL GROWTH FACTOR-LIKE DOMAIN MARKEDLY DECREASES BINDING OF F-VII TO TISSUE FACTOR. The FASEB Journal. A1320-A1320. 1992
- ANTITHROMBIN-III-STOCKHOLM - A POINT MUTATION IN CODON 392 (GLYCINE TO ASPARTIC-ACID) CAUSING IMPAIRED SERINE PROTEASE REACTIVITY. Thrombosis and Haemostasis. 913-913. 1991
- FIBRIN MODERATES THROMBIN INHIBITION BY ANTITHROMBIN III/HEPARIN BUT NOT THROMBIN INHIBITION BY HEPARIN-COFACTOR II/DERMATAN SULFATE. Thrombosis and Haemostasis. 759-759. 1991
- INHIBITION OF THE AMPLIFICATION REACTIONS OF COAGULATION BY SITE-SPECIFIC INHIBITORS OF ALPHA-THROMBIN. Thrombosis and Haemostasis. 650-650. 1991
- INVOLVEMENT OF THE NH2-TERMINAL DOMAIN OF ANTITHROMBIN-III IN HEPARIN BINDING AND COMPLEX-FORMATION WITH ALPHA-THROMBIN. Thrombosis and Haemostasis. 670-670. 1991
- SITE-DIRECTED MUTAGENESIS OF ALANINE 382 OF HUMAN ANTITHROMBIN-III (AT-III). Thrombosis and Haemostasis. 669-669. 1991
- THE LOW-MOLECULAR-WEIGHT HEPARIN ENOXAPARIN MODERATES FACTOR-VII AND PROTHROMBIN CONSUMPTION ASSOCIATED WITH ELECTIVE KNEE SURGERY. Thrombosis and Haemostasis. 1298-1298. 1991
- Molecular Defects in Human Antithrombin III Deficiency. RECOMBINANT TECHNOLOGY IN HEMOSTASIS AND THROMBOSIS. 133-146. 1991
- THE EFFECT OF GLYCOSAMINOGLYCANS ON VESSEL WALL PERMEABILITY IN RABBITS. ADVANCES IN VASCULAR PATHOLOGY 1990, VOL 3. 201-207. 1990
- ACTIVATION OF PLASMA FACTOR-V BY THROMBIN AND FACTOR-XA - INHIBITION BY HIRUDIN AND THE SYNTHETIC PENTASACCHARIDE WITH HIGH-AFFINITY TO ANTITHROMBIN-III. Thrombosis and Haemostasis. 33-33. 1989
- HEPARIN, DERMATAN SULFATE AND THE SYNTHETIC PENTASACCHARIDE WITH HIGH-AFFINITY TO ATIII INHIBIT COAGULATION BY DELAYING PROTHROMBINASE FORMATION. Thrombosis and Haemostasis. 516-516. 1989
- EFFECTS OF UNFRACTIONATED HEPARIN, DERMATAN SULFATE AND LOW-MOLECULAR WEIGHT HEPARIN ON VESSEL WALL PERMEABILITY IN RABBITS. HEPARIN AND RELATED POLYSACCHARIDES : STRUCTURE AND ACTIVITIES. 245-254. 1989
- PLASMA ANTICOAGULANT MECHANISMS OF HEPARIN, HEPARAN-SULFATE, AND DERMATAN SULFATE. HEPARIN AND RELATED POLYSACCHARIDES : STRUCTURE AND ACTIVITIES. 123-131. 1989
- In vitro production of antiidiotypic antibodies by EBV-transformed B cell lines from renal transplant recipients. Human Immunology. 147-148. 1988
- HEPARIN IS NOT AN EFFICIENT INHIBITOR OF THE FACTOR XA-DEPENDENT ACTIVATION OF FACTOR-V AND FACTOR-VIII. Thrombosis and Haemostasis. 36-36. 1987
- INCREASED SULFATION IMPROVES THE ABILITY OF VESSEL WALL GLYCOSAMINOGLYCANS TO REGULATE THROMBIN ACTIVITY AND PROTHROMBIN ACTIVATION IN PLASMA. Thrombosis and Haemostasis. 126-126. 1987
- ANTIIDIOTYPIC ANTIBODIES AND SUPPRESSOR CELLS (SC) IN PATIENTS RECEIVING DONOR SPECIFIC BLOOD-TRANSFUSIONS (DST). Clinical and Investigative Medicine. A165-A165. 1986
- CONTRIBUTIONS OF ANTI-FACTOR-XA AND ANTI-THROMBIN ACTIVITIES OF GLYCOSAMINOGLYCANS (GAGS) TO THEIR ANTICOAGULANT AND ANTITHROMBOTIC PROPERTIES. Thrombosis and Haemostasis. 97-97. 1985
- EVIDENCE THAT INTACT HUMAN-PLATELETS PROVIDE FACTOR VII-LIKE ACTIVITY FOR THE ACTIVATION OF FACTOR-X BY THE EXTRINSIC COAGULATION PATHWAY. Thrombosis and Haemostasis. 176-176. 1985
- HEPARIN AND PENTOSAN POLYSULFATE INHIBIT THE FORMATION OF PROTHROMBINASE AND TENASE COMPLEXES IN PLASMA DEPLETED OF BOTH ANTITHROMBIN III (ATIII) AND HEPARIN COFACTOR-II (HCII). Thrombosis and Haemostasis. 95-95. 1985
- USE OF POLYCLONAL ANTIBODIES TO FACTOR-VII FOR THE DETECTION OF MONOCLONAL-ANTIBODIES TO FACTOR-VII. Thrombosis and Haemostasis. 263-263. 1985
- HEPARIN SULFATE AND DERMATAN SULFATE INHIBIT THROMBIN GENERATION IN PLASMA. Thrombosis and Haemostasis. 226-226. 1983
- RELEASE OF MULTIVESICULAR BODIES FROM PLATELETS AS SEEN IN SCANNING ELECTRON-MICROSCOPY. Thrombosis and Haemostasis. 166-166. 1983
- HLA-RESTRICTED LYMPHOPROLIFERATIVE RESPONSE TO MN BLOOD-GROUP DETERMINANTS. Transfusion. 609-609. 1981
- RELATIVE CONTRIBUTIONS OF THROMBIN AND ANTITHROMBIN-III AFFINITIES OF HEPARIN FRACTIONS TO THE RATE OF INACTIVATION OF THROMBIN BY ANTITHROMBIN-III. Thrombosis and Haemostasis. 42-42. 1981
- RELATIVE EFFECTS OF STANDARD AND LOW-MOLECULAR WEIGHT HEPARINS ON THE THROMBIN-ANTITHROMBIN-III AND FACTOR XA-ANTITHROMBIN-III REACTION-RATES. Clinical Research. A331-A331. 1981
- The Effects Of Heparin On The Activation Of Factor X And Prothrombin In Antithrombin III-Depleted Plasma. Thrombosis and Haemostasis. 40-40. 1981
- The Influence Of Heparin, Phospholipid And Platelets On The Thrombin Or Factor Xa Inactivation By Antithrombin III. Thrombosis and Haemostasis. 118-118. 1981
- REVERSIBLE INHIBITION OF THE INTRINSIC PATHWAY ACTIVATION OF FACTOR-X BY HEPARIN IN THE ABSENCE OF ANTI-THROMBIN-III. The FASEB Journal. 544-544. 1980
- THE AMOUNT OF BLOOD-GROUP A-ANTIGEN, B-ANTIGEN ON PLATELETS IS PROPORTIONAL TO THE AMOUNT THAT IS FREE IN THE PLASMA. Transfusion. 625-625. 1980
- ABSENCE OF HEMOLYSIS OF T-ACTIVATED RED-CELLS FOLLOWING INFUSION OF BLOOD PRODUCTS. Transfusion. 384-384. 1978
- ABSENCE OF HEMOLYSIS OF T-ACTIVATED RED-CELLS FOLLOWING INFUSION OF BLOOD PRODUCTS. Transfusion. 686-686. 1977
- EFFECT OF PROSTAGLANDIN INHIBITORS ON BLEEDING-TIME IN THROMBOCYTOPENIC RABBITS. Blood. 259-259. 1977
- INVIVO EVALUATION OF HEMOSTATIC FUNCTION OF STORED HUMAN PLATELETS. Thrombosis and Haemostasis. 5-5. 1977
- EFFECTS OF METHYLPREDNISOLONE ON PLATELET-ADHESION TO DAMAGED AORTA, BLEEDING-TIME AND PLATELET SURVIVAL. Blood. 1009-1009. 1976
- HEMOSTATIC FUNCTION OF STORED HUMAN PLATELETS IN RABBITS - LACK OF CORRELATION WITH INVIVO AND INVITRO PLATELET-AGGREGATION. Clinical Research. A437-A437. 1976
- MODEL FOR INVIVO EVALUATION OF HEMOSTATIC FUNCTION OF STORED HUMAN PLATELETS. Transfusion. 525-526. 1976
-
journal articles
- Age of Transfused Blood in Critically Ill Adults. New England Journal of Medicine. 372:1410-1418. 2015
- Effects of Red-Cell Storage Duration on Patients Undergoing Cardiac Surgery. New England Journal of Medicine. 372:1419-1429. 2015
- Regulatory decisions pertaining to aprotinin may be putting patients at risk. CANADIAN MEDICAL ASSOCIATION JOURNAL. 186:1379-1386. 2014
- Effect of Fresh Red Blood Cell Transfusions on Clinical Outcomes in Premature, Very Low-Birth-Weight Infants. Journal of the American Medical Association (JAMA). 308:1443-1443. 2012
- ERRATA. Transfusion. 52:1842-1842. 2012
- The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. Transfusion. 52:1363-1378. 2012
- Clinical trial opportunities in hemostasis and thrombosis: NHBLI State‐of‐the‐science symposium. American Journal of Hematology. 87:235-238. 2012
- Proceedings of a Consensus Conference: Risk-Based Decision Making for Blood Safety. Transfusion Medicine Reviews. 25:267-292. 2011
- The Age of Blood Evaluation (ABLE) Randomized Controlled Trial: Study Design. Transfusion Medicine Reviews. 25:197-205. 2011
- A multidisciplinary “think tank”: the top 10 clinical trial opportunities in transfusion medicine from the National Heart, Lung, and Blood Institute–sponsored 2009 state‐of‐the‐science symposium. Transfusion. 51:828-841. 2011
- Clinical review: Canadian National Advisory Committee on Blood and Blood Products - Massive Transfusion Consensus Conference 2011: report of the panel. Critical Care. 15:242-242. 2011
- Clinical Trial Opportunities in Transfusion Medicine: Proceedings of a National Heart, Lung, and Blood Institute State-of-the-Science Symposium. Transfusion Medicine Reviews. 24:259-285. 2010
- Blood Still Kills: Six Strategies to Further Reduce Allogeneic Blood Transfusion-Related Mortality. Transfusion Medicine Reviews. 24:77-124. 2010
- Extending the Horizon for Cell-Based Immunotherapy by Understanding the Mechanisms of Action of Photopheresis. Transfusion Medicine Reviews. 24:22-32. 2010
- Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. Transfusion. 49:1262-1268. 2009
- Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 113:3406-3417. 2009
- Severe Hemolytic Anemia Post–Renal Transplantation Produced by Donor Anti-D Passenger Lymphocytes: Case Report and Literature Review. Transfusion Medicine Reviews. 23:155-159. 2009
- Neurodevelopmental Outcome of Extremely Low Birth Weight Infants Randomly Assigned to Restrictive or Liberal Hemoglobin Thresholds for Blood Transfusion. Pediatrics. 123:207-213. 2009
- The Age of Red Blood Cells in Premature Infants (ARIPI) Randomized Controlled Trial: Study Design. Transfusion Medicine Reviews. 23:55-61. 2009
- Human FVII(K62E) does not exhibit enhanced binding to tissue factor. Journal of Thrombosis and Haemostasis. 6:1229-1229. 2008
- A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery. New England Journal of Medicine. 358:2319-2331. 2008
- Transfusion‐related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen. Transfusion. 48:814-821. 2008
- Why implement universal leukoreduction?. Hematology/Oncology and Stem Cell Therapy. 1:106-123. 2008
- CD200-dependent and nonCD200-dependant pathways of NK cell suppression by human IVIG. Journal of Assisted Reproduction and Genetics. 25:67-72. 2008
- A multicenter pilot‐randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion. 48:81-91. 2008
- New Strategies for the Optimal Use of Platelet Transfusions. Hematology. American Society of Hematology. Education Program. 2008:198-204. 2008
- Proceedings of a Consensus Conference: Pathogen Inactivation—Making Decisions About New Technologies. Transfusion Medicine Reviews. 22:1-34. 2008
- Transfusion-related immunomodulation (TRIM): An update. Blood Reviews. 21:327-348. 2007
- Passive Transfer of Peanut Hypersensitivity by Fresh Frozen Plasma. JAMA Internal Medicine. 167:853-853. 2007
- Research Ethics Boards: The Protection of Human Subjects. PLoS Medicine. 3:e472-e472. 2006
- The Continuing Risk of Transfusion-Transmitted Infections. New England Journal of Medicine. 355:1303-1305. 2006
- The premature infants in need of transfusion (pint) study: A randomized, controlled trial of a restrictive (LOW) versus liberal (HIGH) transfusion threshold for extremely low birth weight infants. Journal of Pediatrics. 149:301-307.e3. 2006
- Discussion. JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE. 60:S24-S25. 2006
- Discussion. JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE. 60:S33-S34. 2006
- Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol - Discussion. JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE. 60:S95-S96. 2006
- The Clinical Benefits of the Leukoreduction of Blood Products. Journal of Trauma and Acute Care Surgery. 60:S83-S90. 2006
- The clinical benefits of the leukoreduction of blood products - Discussion. JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE. 60:S88-S90. 2006
- Avoiding Transfusions in Children Undergoing Cardiac Surgery: A Meta-Analysis of Randomized Trials of Aprotinin. Anesthesia and Analgesia. 102:731-737. 2006
- In vivo recovery and survival of apheresis and whole blood‐derived platelets: a paired comparison in healthy volunteers. Transfusion. 46:257-264. 2006
- LETTERS TO THE EDITOR. Journal of Trauma and Acute Care Surgery. 60:242-243. 2006
- Transfusion-related acute lung injury. Current Opinion in Hematology. 12:480-487. 2005
- Bacterial Detection of Platelets: Current Problems and Possible Resolutions. Transfusion Medicine Reviews. 19:259-272. 2005
- Landmark studies that have changed the practice of transfusion medicine. Transfusion. 45:1523-1530. 2005
- Transfusion immunomodulation or TRIM: What does it mean clinically?. Hematology. 10:208-214. 2005
- Assessing the effectiveness of whole blood–derived platelets stored as a pool: a randomized block noninferiority trial. Transfusion. 45:896-903. 2005
- In vitro evaluation of prestorage pooled leukoreduced whole blood–derived platelets stored for up to 7 days. Transfusion. 45:904-910. 2005
- Interspecies exchange mutagenesis of the first epidermal growth factor‐like domain of human factor VII. Journal of Thrombosis and Haemostasis. 3:1250-1256. 2005
- A Pilot Trial Evaluating the Clinical Effects of Prolonged Storage of Red Cells. Anesthesia and Analgesia. 100:1433-1458. 2005
- Protecting the Blood Supply From Emerging Pathogens: The Role of Pathogen Inactivation. Transfusion Medicine Reviews. 19:110-126. 2005
- Revisiting transfusion practices in critically ill patients*. Critical Care Medicine. 33:7-12. 2005
- Toward an understanding of transfusion‐related acute lung injury: statement of a consensus panel. Transfusion. 44:1774-1789. 2004
- Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage. Transfusion. 44:1361-1366. 2004
- Is a Restrictive Transfusion Strategy Safe for Resuscitated and Critically Ill Trauma Patients?. Journal of Trauma and Acute Care Surgery. 57:563-568. 2004
- The top ten list of randomized controlled trials in transfusion medicine. Vox Sanguinis. 87:193-196. 2004
- ES08.02 Bacterial contamination of cellular blood components: risks, sources and control. Vox Sanguinis. 87:98-103. 2004
- Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: effluxing fibrin(ogen) fragments contain antiangiogenic activity. Translational Research. 143:241-254. 2004
- Proceedings of a consensus conference: the screening of blood donors for variant CJD1 1This Consensus Conference took place at the Ritz Carlton Hotel in Montreal, Quebec, on March 26–28, 2003, and was chaired by Dr. Gilles Delage of Héma Québec.. Transfusion Medicine Reviews. 18:73-92. 2004
- Improving the bacteriological safety of platelet transfusions. Transfusion Medicine Reviews. 18:11-24. 2004
- Transfusion-related acute lung injury. Transfusion Medicine Reviews. 17:252-262. 2003
- Leukoreduction vs Buffy-Coat Depletion and the Safety of Blood Transfusion. Journal of the American Medical Association (JAMA). 290:1580-1580. 2003
- Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. Journal of Thrombosis and Haemostasis. 1:1637-1641. 2003
- Clinical Outcomes Following Institution of Universal Leukoreduction of Blood Transfusions for Premature Infants. Journal of the American Medical Association (JAMA). 289:1950-1950. 2003
- Clinical Outcomes Following Institution of the Canadian Universal Leukoreduction Program for Red Blood Cell Transfusions. Journal of the American Medical Association (JAMA). 289:1941-1941. 2003
- How Should Canada Fund the Blood System? An Evaluation of the Chargeback Proposal. Healthcare Quarterly. 6:47-54. 2003
- GUTI: a new antigen in the Cromer blood group system. Transfusion. 43:340-344. 2003
- Bacterial Contamination of Blood Components: Risks, Strategies, and Regulation. Hematology. American Society of Hematology. Education Program. 2003:575-589. 2003
- Consumption of plasma factor VII in a rabbit model of non-overt disseminated intravascular coagulation. Thrombosis Research. 108:329-334. 2002
- Immunomodulation and Blood Transfusion. American Journal of Therapeutics. 9:389-395. 2002
- A randomized controlled trial comparing the frequency of acute reactions to plasma‐removed platelets and prestorage WBC‐reduced platelets. Transfusion. 42:556-566. 2002
- Angiostatin II is the predominant glycoform in pleural effusates of rabbit VX-2 lung tumors. Translational Research. 139:316-323. 2002
- Incidence and significance of the bacterial contamination of blood components.. Developments in Biologicals. 108:59-67. 2002
- Bacterial contamination of platelet concentrates: Incidence, significance, and prevention. Seminars in Hematology. 38:20-26. 2001
- Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases?*. Critical Care Medicine. 29:S181-S188. 2001
- Metabolism of rabbit plasma-derived factor VII in relation to prothrombin in rabbits. American Journal of Physiology - Endocrinology and Metabolism. 281:E507-E515. 2001
- Novel treatment modalities: new platelet preparations and subsititutes. British Journal of Haematology. 114:496-505. 2001
- Universal leucocyte‐depletion of blood components: cell concentrates and plasma. Vox Sanguinis. 81:56-77. 2001
- Bacterial contamination of blood products. Transfusion and Apheresis Science. 24:245-245. 2001
- Do Blood Transfusions Improve Outcomes Related to Mechanical Ventilation?. Chest. 119:1850-1857. 2001
- Novel platelet products, substitutes and alternatives. Transfusion Clinique et Biologique. 8:267-271. 2001
- Red blood cell transfusion strategies. Transfusion Clinique et Biologique. 8:207-210. 2001
- Universal WBC reduction:the case for and against. Transfusion. 41:691-712. 2001
- Clinical and molecular basis of transfusion-induced immunomodulation: summary of the proceedings of a state-of-the-art conference*. Transfusion Medicine Reviews. 15:108-135. 2001
- A second example of a transfusion‐associated septic reaction associated with Clostridium perfringens. Transfusion. 41:427-428. 2001
- Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?. Blood. 97:1180-1195. 2001
- Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases?. Critical Care Medicine. 29:227-234. 2001
- Proceedings of a Consensus Conference: Prevention of Post-Transfusion CMV in the Era of Universal Leukoreduction1. Transfusion Medicine Reviews. 15:1-20. 2001
- Rapid in vivo induction of leukocyte tissue factor mRNA and protein synthesis following low dose endotoxin administration to rabbits. Hematology Journal. 2:188-195. 2001
- Comparison of post transfusion platelet response following random donor and apheresis platelets. Blood. 96. 2000
- o-Raffinose cross-linked hemoglobin improves the hemostatic defect associated with anemia and thrombocytopenia in rabbits. Blood. 96:3630-3636. 2000
- Activation and Active Site Occupation Alter Conformation in the Region of the First Epidermal Growth Factor-like Domain of Human Factor VII. Journal of Biological Chemistry. 275:34894-34900. 2000
- Bacterial contamination of cellular blood products: the Canadian perspective. Transfusion and Apheresis Science. 23:17-19. 2000
- Mutation of Any Site of N-Linked Glycosylation Accelerates the In Vivo Clearance of Recombinant Rabbit Antithrombin. Thrombosis Research. 99:407-415. 2000
- RBC T activation and hemolysis: implications for pediatric transfusion management. Transfusion. 40:801-812. 2000
- Expression and Purification of Recombinant Rabbit Factor VII. Thrombosis Research. 98:203-211. 2000
- Platelet substitutes and novel platelet products. Expert Opinion on Investigational Drugs. 9:457-469. 2000
- Bacterial Contamination of Blood Components. Vox Sanguinis. 78:59-67. 2000
- Effect of the Factor V Leiden Mutation on the Clinical Expression of Severe Hemophilia A. Thrombosis and Haemostasis. 83:387-391. 2000
- Platelet substitutes.. Vox Sanguinis. 78 Suppl 2:183-186. 2000
- Prestorage versus poststorage white cell reduction for the prevention of the deleterious immunomodulatory effects of allogeneic blood transfusion. Transfusion Medicine Reviews. 14:23-33. 2000
- Reducing the risk of bacterial contamination of cellular blood components.. Developments in Biologicals. 102:183-193. 2000
- A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care (vol 340, pg 409, 1999). New England Journal of Medicine. 340:1056-1056. 1999
- A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care. New England Journal of Medicine. 340:409-417. 1999
- A novel and de novo spontaneous point mutation (Glu271STOP) of the antithrombin gene results in a type I deficiency and thrombophilia. American Journal of Hematology. 60:126-129. 1999
- The Clearance of Thrombin-antithrombin and Related Serpin-enzyme Complexes from the Circulation: Role of Various Hepatocyte Receptors. Thrombosis and Haemostasis. 81:325-337. 1999
- The Procoagulant State of the VX-2 Tumor in Rabbit Lung In Vivo. Thrombosis and Haemostasis. 82:1694-1702. 1999
- Uptake of heparin cofactor II and antithrombin into the aorta wall after a deendothelializing injury in vivo: Comparison with the behaviors of prothrombin and fibrinogen. Translational Research. 133:81-87. 1999
- Variation in red cell transfusion practice in the intensive care unit: a multicentre cohort study. Critical Care. 3:57-63. 1999
- In Vivo Clearance of Ternary Complexes of Vitronectin-Thrombin-Antithrombin Is Mediated by Hepatic Heparan Sulfate Proteoglycans. Journal of Biological Chemistry. 273:23440-23447. 1998
- Novel platelet products and substitutes. Transfusion Medicine Reviews. 12:175-187. 1998
- Bacterial Contamination and Proliferation during the Storage of Cellular Blood Products. Vox Sanguinis. 74:155-159. 1998
- Immunomodulatory Effects of Allogeneic Blood Transfusions: Clinical Manifestations and Mechanisms. Vox Sanguinis. 74:315-319. 1998
- A Canadian survey of transfusion practices in critically ill patients. Critical Care Medicine. 26:482-487. 1998
- A new tool for communicating transfusion risk information. Transfusion. 38:184-188. 1998
- Factor VII Deficiency Caused by a Structural Variant N57D of the First Epidermal Growth Factor Domain. Blood. 91:142-148. 1998
- Comparative catabolism of prothrombin and antithrombin in normal and alloxan-diabetic rabbits. Metabolism: Clinical and Experimental. 46:1406-1411. 1997
- Cytokeratin 18 Is Expressed on the Hepatocyte Plasma Membrane Surface and Interacts with Thrombin-Antithrombin Complexes. Journal of Biological Chemistry. 272:28574-28581. 1997
- IMPACT OF MUTATIONS AT THE P4 AND P5 POSITIONS ON THE REACTION OF ANTITHROMBIN WITH THROMBIN AND ELASTASE. Thrombosis Research. 88:171-181. 1997
- Psoralen‐mediated photodecontamination of platelet concentrates: inactivation of cell‐free and cell‐associated forms of human immunodeficiency virus and assessment of platelet function in vivo. Transfusion. 37:889-895. 1997
- A proposal for an individual patient data based meta-analysis of randomized controlled trials of allogeneic transfusion and postoperative bacterial infection. Transfusion Medicine Reviews. 11:180-194. 1997
- Review of the clinical practice literature on allogeneic red blood cell transfusion. CANADIAN MEDICAL ASSOCIATION JOURNAL. 156:S9-S26. 1997
- Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits. American Journal of Physiology - Endocrinology and Metabolism. 272:E824-E831. 1997
- Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits. American Journal of Physiology. 272:E824-E831. 1997
- Does transfusion practice affect mortality in critically ill patients?. American Journal of Respiratory and Critical Care Medicine. 155:1618-1623. 1997
- Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group.. American Journal of Respiratory and Critical Care Medicine. 155:1618-1623. 1997
- The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes. Transfusion Medicine Reviews. 11:95-105. 1997
- Regions Flanking Exon 1 Regulate Constitutive Expression of the Human Antithrombin Gene. Journal of Biological Chemistry. 271:29502-29512. 1996
- Activation of a recombinant human factor VII structural analogue alters its affinity of binding to tissue factor. American Journal of Hematology. 53:66-71. 1996
- An Increased Uptake of Prothrombin, Antithrombin, and Fibrinogen by the Rabbit Balloon-Deendothelialized Aorta Surface In Vivo Is Maintained Until Reendothelialization Is Complete. Arteriosclerosis, Thrombosis and Vascular Biology. 16:1147-1155. 1996
- Age‐related changes in factor VII proteolysis in vivo. British Journal of Haematology. 94:407-412. 1996
- Prevalence of factor V Leiden in a Canadian blood donor population.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 155:285-289. 1996
- Current Research on the Immunomodulatory Effect of Allogeneic Blood Transfusion. Vox Sanguinis. 70:187-194. 1996
- Treatment of T. cruzi infected human platelet concentrates with aminomethyltrimethyl psoralen (AMT) and ultravioleta (UV-A) light: preliminary results. Revista da Sociedade Brasileira de Medicina Tropical. 29:47-49. 1996
- Plasmin accelerates platelet‐dependent prothrombinase formation without activating the platelets. British Journal of Haematology. 92:458-465. 1996
- Catabolism of rabbit prothrombin in rabbits: uptake of prothrombin by the aorta wall before and after a de-endothelializing injury in vivo.. Translational Research. 126:521-529. 1995
- Intracellular events determine the fate of antithrombin Utah. Blood. 86:3461-3467. 1995
- Prevention of transfusion‐associated Chagas' disease: efficacy of white cell‐reduction filters in removing Trypanosoma cruzi from infected blood. Transfusion. 35:723-726. 1995
- Noninfectious adverse effects of blood transfusion in the neonate.. Transfusion Medicine Reviews. 9:277-287. 1995
- Three examples of Rh haemolytic disease of the newborn with a negative direct antiglobulin test. Transfusion Medicine. 5:113-116. 1995
- Deletion mutagenesis of heparin cofactor II: defining the minimum size of a thrombin inhibiting serpin. FEBS Letters. 365:189-192. 1995
- TRANSFUSION REQUIREMENTS IN CRITICAL CARE - A PILOT-STUDY. Journal of the American Medical Association (JAMA). 273:1439-1444. 1995
- Transfusion requirements in critical care. A pilot study. Canadian Critical Care Trials Group. Journal of the American Medical Association (JAMA). 273:1439-1444. 1995
- Immunosuppressive Effects of Allogeneic Blood Transfusions: Implications for the Patient with a Malignancy. Hematology/Oncology Clinics of North America. 9:205-218. 1995
- The leukodepletion of cellular blood products in the prevention of HLA- alloimmunization and refractoriness to allogeneic platelet transfusions [editorial]. Blood. 85:603-606. 1995
- Bacterial Contamination of Blood Products and the Value of Pre-Transfusion Testing. Immunological Investigations. 24:163-170. 1995
- Inhibition of Thrombin by Antithrombin III and Heparin Cofactor II In Vivo. Thrombosis and Haemostasis. 73:405-412. 1995
- Post-transfusion hepatitis: impact of non-A, non-B hepatitis surrogate tests. The Lancet. 345:21-25. 1995
- The Tumor Growth-Promoting Effect of Allogeneic Blood Transfusions. Immunological Investigations. 24:311-317. 1995
- Mechanisms of transfusion-associated immunosuppression.. Current Opinion in Hematology. 1:457-461. 1994
- Understanding the Polymerase Chain Reaction. Transfusion Medicine Reviews. 8:242-252. 1994
- Biologic effects of leukocytes present in transfused cellular blood products. Blood. 84:1703-1721. 1994
- Efficacy of leukodepletion filters in removing T. cruzi from contaminated blood. Revista da Sociedade Brasileira de Medicina Tropical. 27:175-175. 1994
- Amino acid substitutions of the P2 residue of human antithrombin that either enhance or impair function. Thrombosis Research. 75:293-305. 1994
- BACTERIAL CONTAMINATION OF CELLULAR BLOOD COMPONENTS. Vox Sanguinis. 67:25-33. 1994
- Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of the timing of the leukodepletion. Blood. 84:344-348. 1994
- Hemolytic and Pseudo-Hemolytic Transfusion Reactions: An Overview of the Hemolytic Transfusion Reactions and the Clinical Conditions That Mimic Them. Transfusion Medicine Reviews. 8:184-199. 1994
- Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor. Blood. 83:3524-3535. 1994
- Genetic linkage studies in antithrombin‐deficient kindreds using a highly polymorphic trinucleotide short tandem repeat (str) within the human antithrombin gene. American Journal of Hematology. 46:107-111. 1994
- Molecular cloning and expression of rabbit heparin cofactor II: a plasma thrombin inhibitor highly conserved between species.. Thrombosis and Haemostasis. 71:778-782. 1994
- Characterization of a highly polymorphic trinucleotide short tandem repeat within the human antithrombin gene. Thrombosis Research. 74:303-307. 1994
- Prevalence of antithrombin deficiency in healthy blood donors: A cross‐sectional study. American Journal of Hematology. 45:321-324. 1994
- Trinucleotide repeat polymorphism within the human antithrombin gene (AT3): allele frequency data for three population groups. Molecular and Cellular Probes. 8:149-154. 1994
- Site‐directed mutagenesis of the P2 residue of human antithrombin. FEBS Letters. 339:147-150. 1994
- Defining the heparin-binding domain of antithrombin. Blood Coagulation and Fibrinolysis. 5:83-96. 1994
- Microheterogeneity of antithrombin III. Blood Coagulation and Fibrinolysis. 5:7-16. 1994
- The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals. British Journal of Haematology. 86:347-350. 1994
- An overview of the mechanism of action of antithrombin and its inherited deficiency states. Blood Coagulation and Fibrinolysis. 5:S5-12. 1994
- Canadian Red Cross Society Symposium on Leukodepletion: Report of Proceedings. Transfusion Medicine Reviews. 8:1-14. 1994
- Molecular Cloning and Expression of Rabbit Heparin Cofactor II: A Plasma Thrombin Inhibitor Highly Conserved between Species. Thrombosis and Haemostasis. 71:778-782. 1994
- Panel Discussion. Blood Coagulation and Fibrinolysis. 5:S59-S59. 1994
- Platelet concentrates stored for 5 days in a reduced volume of plasma maintain hemostatic function and viability. Transfusion. 34:44-47. 1994
- Assessment of the hemostatic effectiveness of human platelets treated with aminomethyltrimethyl psoralen and UV A light using a rabbit ear bleeding time technique. Blood. 82:3489-3492. 1993
- Experimental animal model of refractoriness to donor platelets: the effect of plasma removal and the extent of white cell reduction on allogeneic alloimmunization. Transfusion. 33:798-801. 1993
- Nucleotide sequences of an antiidiotypic antibody from a transplant recipient. Immunogenetics. 38:242. 1993
- The direct binding of human factor VII in plasma to recombinant human tissue factor. Thrombosis Research. 70:307-316. 1993
- The Incidence of Post-Transfusion Hepatitis. New England Journal of Medicine. 328:1280-1281. 1993
- Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells [see comments]. Blood. 81:1880-1882. 1993
- An Antithrombin III Assay Based on Factor Xa Inhibition Provides a More Reliable Test to Identify Congenital Antithrombin III Deficiency Than an Assay Based on Thrombin Inhibition. Thrombosis and Haemostasis. 69:231-235. 1993
- Antithrombin III Mutation Database: First Update. Thrombosis and Haemostasis. 70:361-369. 1993
- Complete nucleotide sequence of the cdna encoding rabbit coagulation factor VII. Thrombosis Research. 69:231-238. 1993
- Frequent association of factor VII defects with other clotting disorders. Blood Coagulation and Fibrinolysis. 3:831-834. 1992
- Frequent association of factor VII defects with other clotting disorders. Blood Coagulation and Fibrinolysis. 3:829-830. 1992
- Molecular basis of inherited human antithrombin deficiency. Blood. 80:2159-2171. 1992
- Prophylactically equivalent doses of Enoxaparin and unfractionated heparin inhibit in vivo coagulation to the same extent. British Journal of Haematology. 82:400-405. 1992
- The low molecular weight heparin Enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery. British Journal of Haematology. 82:391-399. 1992
- Partial deletion of an antithrombin III allele in a kindred with a type 1 deficiency. Blood. 80:1476-1485. 1992
- A novel congenital haemostatic defect. Blood Coagulation and Fibrinolysis. 3:357-360. 1992
- Analysis of a Pregnancy-Screening and Neonatal-Immunization Program for Hepatitis B in Hamilton, Ontario, Canada, 1977–1988. Obstetrical and Gynecological Survey. 47:301-302. 1992
- Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of α-thrombin. Biochemical Journal. 283:893-897. 1992
- Molecular cloning and expression of rabbit antithrombin III. Blood. 79:2330-2339. 1992
- Thrombosis in Antithrombin-III-deficient Persons. ACP journal club. 116:754-761. 1992
- Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity. Blood. 79:1428-1434. 1992
- An animal model of allogeneic donor platelet refractoriness: the effect of the time of leukodepletion. Blood. 79:1371-1375. 1992
- Effect of allogeneic blood transfusion on solid tumor growth and pulmonary metastases in mice. Journal of Cancer Research and Clinical Oncology. 118:176-180. 1992
- The N-terminal domain of antithrombin-III is essential for heparin binding and complex-formation with, but not cleavage by, α-thrombin. Biochemical Journal. 282:345-351. 1992
- The first epidermal growth factor domain of human coagulation factor VII is essential for binding with tissue factor. FEBS Letters. 298:206-210. 1992
- A useful restriction analysis for the determination of human antithrombin III variants with mutations from Ala 382 to Ala 384. Thrombosis Research. 65:117-120. 1992
- Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082. The FEBS Journal. 203:121-125. 1992
- Measurement of Markers of Activated Coagulation in Antithrombin III Deficient Subjects. Thrombosis and Haemostasis. 67:542-544. 1992
- Molecular Cloning and Cell-Free Expression of Mouse Antithrombin III. Thrombosis and Haemostasis. 68:291-296. 1992
- Pseudopolycythemia, pseudothrombocytopenia, and pseudoleukopenia due to overfilling of blood collection vacuum tubes.. Archives of Pathology and Laboratory Medicine. 116:90-92. 1992
- Effect of blood transfusion on survival in a mouse bacterial peritonitis model. Transfusion. 31:710-712. 1991
- Analysis of a pregnancy‐screening and neonatal‐immunization program for hepatitis B in Hamilton, Ontario, Canada, 1977‐1988. Journal of Medical Virology. 35:50-54. 1991
- The effect of leukodepletion on allogeneic donor platelet survival and refractoriness in an animal model.. Seminars in Hematology. 28:14-17. 1991
- Overestimation of fetomaternal haemorrhage by the acid‐elution technique in mothers with β‐thalassaemia minor. Transfusion Medicine. 1:129-132. 1991
- Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa. Blood. 77:2185-2189. 1991
- Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.. Translational Research. 117:359-364. 1991
- Site‐directed mutagenesis of alanine‐382 of human antithrombin III. FEBS Letters. 280:254-258. 1991
- MOLECULAR GENETIC-BASIS FOR THE ANTIIDIOTYPIC ANTIBODY-RESPONSE ASSOCIATED WITH SUCCESSFUL RENAL-ALLOGRAFT SURVIVAL IN HUMANS. Transplantation Proceedings. 23:1059-1061. 1991
- Molecular genetic basis for the antiidiotypic antibody response associated with successful renal allograft survival in humans.. Transplantation Proceedings. 23:1059-1061. 1991
- Antithrombin III‐Amiens: A new family with an Arg47 → cys inherited variant of antithrombin iii with impaired heparin cofactor activity. American Journal of Hematology. 36:25-29. 1991
- Blood Product-Associated Bacterial Sepsis. Transfusion Medicine Reviews. 5:73-83. 1991
- Erratum. Mitochondrial DNA Part A: DNA Mapping, Sequencing, and Analysis. 1:427-427. 1991
- Evaluation of pediatric transfusion practice using criteria maps. Transfusion. 31:52-58. 1991
-
Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and
d -Phe-Pro-Arg-Ch2Cl. Biochemical Journal. 272:399-406. 1990 - Expression in a cell-free system of normal and variant forms of human antithrombin III. Ability to bind heparin and react with alpha-thrombin. Blood. 76:1521-1529. 1990
- Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma. The FEBS Journal. 193:485-493. 1990
- Antithrombin III Sudbury: An Ala384 → pro mutation with abnormal thrombin-binding activity and thrombotic diathesis. Thrombosis Research. 59:793-797. 1990
- Envelope glycoprotein of avian hemangioma retrovirus induces a thrombogenic surface on human and bovine endothelial cells. Journal of Virology. 64:4029-4032. 1990
- EFFECT OF BLOOD TRANSFUSIONS ON EXPERIMENTAL PULMONARY METASTASIS IN MICE. Transfusion. 30:188-190. 1990
- Incorporation of 7-deaza dGTP during the amplification step in the polymerase chain reaction procedure improves subsequent DNA sequencing. Mitochondrial DNA Part A: DNA Mapping, Sequencing, and Analysis. 1:137-140. 1990
- The Antithrombotic Properties of Human Prothrombin Fragment 1.2 in Mice. Thrombosis and Haemostasis. 63:413-416. 1990
- The Molecular Pathology of Inherited Human Antithrombin III Deficiency. Transfusion Medicine Reviews. 3:264-281. 1989
- Agreement study between two laboratories of immunofluorescence as a confirmatory test for human immunodeficiency virus type 1 antibody screening. Journal of Clinical Microbiology. 27:1234-1237. 1989
- Effects of Unfractionated Heparin, Dermatan Sulfate and Low Molecular Weight Heparin on Vessel Wall Permeability in Rabbitsa. Annals of the New York Academy of Sciences. 556:245-254. 1989
- Plasma Anticoagulant Mechanisms of Heparin, Heparan Sulfate, and Dermatan Sulfatea. Annals of the New York Academy of Sciences. 556:123-131. 1989
- The Role of Red Blood Cell Antigens, Histocompatibility Antigens, and Blood Transfusions on Renal Allograft Survival. Transfusion Medicine Reviews. 3:171-179. 1989
- A prospective study evaluating the lowering of hemoglobin standards for blood donors. Transfusion. 29:268-272. 1989
- ANTIIDIOTYPIC ANTIBODIES - PRODUCTION INVITRO BY EBV-TRANSFORMED LYMPHOBLASTOID CELL-LINES AND IMMUNOCHEMICAL CHARACTERIZATION OF IDIOTYPIC RECEPTORS ON T-CELLS. Transplantation Proceedings. 21:333-335. 1989
- Antiidiotypic antibodies: production in vitro by EBV-transformed lymphoblastoid cell lines and immunochemical characterization of idiotypic receptors on T-cells.. Transplantation Proceedings. 21:333-335. 1989
- Molecular analysis of the HLA-D region and the T-cell antigen receptor beta-chain genes in monozygotic twins discordant for rheumatoid arthritis.. Transplantation Proceedings. 21:632-634. 1989
- Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochemical Journal. 257:143-150. 1989
- Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity. Blood. 72:1518-1523. 1988
- Production in vitro of antibodies directed against alloantigen-specific recognition sites on T cells and on lymphocytotoxic HLA antibodies.. Clinical and Experimental Immunology. 72:222-227. 1988
- An Approach to Assigning In Vitro Potency to Unfractionated and Low Molecular Weight Heparins Based on the Inhibition of Prothrombin Activation and Catalysis of Thrombin Inhibition. Thrombosis and Haemostasis. 60:193-198. 1988
- Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate. Biochemical Journal. 248:889-896. 1987
- Anti-idiotypic antibodies and suppressor cells in patients receiving pretransplant donor-specific blood transfusions.. Transplantation Proceedings. 19:3399-3401. 1987
- The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochemical Journal. 243:579-588. 1987
- Use of Plasma Segments for Estimating Factor VIII Activity in Pools of Fresh Frozen Plasma. Vox Sanguinis. 52:254-256. 1987
- Evidence for an alternative mechanism of human platelet secretion involving peripheralization of secretory granules and formation of membrane-associated multivesicular structures. Thrombosis Research. 45:771-782. 1987
- THE BLOOD-TRANSFUSION EFFECT - CHARACTERIZATION OF T-CELL ALLOANTIGEN-SPECIFIC RECEPTORS BY SERA FROM TRANSFUSED MICE. Transplantation Proceedings. 19:1429-1431. 1987
- The blood transfusion effect: characterization of T cell alloantigen-specific receptors by sera from transfused mice.. Transplantation Proceedings. 19:1429-1431. 1987
- INDUCTION OF ANTIIDIOTYPIC ANTIBODIES BY BLOOD TRANSFUSIONS. Transplantation. 42:632-635. 1986
- Mechanisms for Inhibition of the Generation of Thrombin Activity by Sulfated Polysaccharidesa. Annals of the New York Academy of Sciences. 485:41-55. 1986
- BLOOD TRANSFUSION AND RENAL TRANSPLANTATION. British Journal of Haematology. 61:595-602. 1985
- The immunodepletion of factor VII from human plasma using a monoclonal antibody. British Journal of Haematology. 61:467-475. 1985
- Approaches to the measurement of the response to Factor VIII concentrate infusion. Thrombosis Research. 39:429-437. 1985
- The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate. British Journal of Haematology. 60:695-704. 1985
- Association of renal failure with lewis incompatibility after allogeneic bone marrow transplantation. American Journal of Medicine. 79:143-146. 1985
- Use of Segments for the Quality Control of the Factor VIII: Coagulant Activity of Fresh Frozen Plasma. Vox Sanguinis. 48:213-216. 1985
- The isolation of prothrombin, factor IX and factor X from human factor IX concentrates. Thrombosis Research. 36:537-547. 1984
- Quantitation of red cell‐associated IgG using an immunoradiometric assay. Transfusion. 24:473-476. 1984
- Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III. Biochemistry and Cell Biology. 62:975-983. 1984
- Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood. 64:742-747. 1984
- Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.. Blood. 64:742-747. 1984
- The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor. British Journal of Haematology. 57:229-238. 1984
- Neonatal cytomegalovirus infections: the relative role of neonatal blood transfusion and maternal exposure.. Clinical and Investigative Medicine. 7:13-19. 1984
- Substitution of the “group-and-screen” for the full crossmatch in elective operations. Canadian Journal of Anaesthesia. 30:641-645. 1983
- Quantitation of red cell membrane associated immunoglobulin in children with Plasmodium falciparum parasitaemia. British Journal of Haematology. 54:567-572. 1983
- Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thrombosis Research. 28:487-497. 1982
- Inhibition of arterial thrombosis and platelet function by nafazatrom. Thrombosis Research. 28:157-170. 1982
- HLA-restricted lymphoproliferative responses to MN blood group determinants. Nature. 299:67-69. 1982
- The amount of blood group A substance on platelets is proportional to the amount in the plasma. Blood. 59:980-985. 1982
- Alloantibodies and Platelet Destruction. Seminars in Vascular Medicine. 8:105-115. 1982
- HLA-restricted responses to M and N determinants in the primed lymphocyte test. Human Immunology. 3:325-335. 1981
- Hemostatic Function, Survival, and Membrane Glycoprotein Changes in Young versus Old Rabbit Platelets. Journal of Clinical Investigation. 68:1289-1294. 1981
- Activation of factor X and prothrombin in antithrombin-III depleted plasma: The effects of heparin. Thrombosis Research. 23:331-345. 1981
- Transient Donath‐Landsteiner Haemolytic Anaemia. British Journal of Haematology. 48:425-434. 1981
- Studies on the blood of an MiV homozygote. Transfusion. 21:1-14. 1981
- The factor VIII-independent activation of factor X by factors IXa and VII in plasma. Thrombosis Research. 21:23-33. 1981
- The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III. Thrombosis Research. 20:391-403. 1980
- Immunodepletion of human plasma factor VIII. Blood. 56:604-607. 1980
- Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography. Thrombosis Research. 20:77-83. 1980
- The thrombogenicity of prothrombin complex concentrates: I. The relationship between characteristics and thrombogenicity in rabbits. Thrombosis Research. 17:353-366. 1980
- The thrombogenicity of prothrombin complex concentrates: II. The effect of thrombocytopenia on in vivo thrombogenicity in rabbits. Thrombosis Research. 17:555-560. 1980
- Prostaglandin I2 (prostacyclin).. CANADIAN MEDICAL ASSOCIATION JOURNAL. 122:175-179. 1980
- Shortening of the bleeding time in thrombocytopenic rabbits after exposure of jugular vein to high aspirin concentration. Prostaglandins Leukotrienes and Essential Fatty Acids. 3:333-342. 1979
- Platelet transfusions.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 121:1353-1358. 1979
- The spectrum of ABO hemolytic disease of the newborn infant. Journal of Pediatrics. 95:447-449. 1979
- ABO haemolytic disease of the new born.. East African Medical Journal. 56:314-319. 1979
- Shortening of the Bleeding Time in Rabbits by Hydrocortisone Caused by Inhibition of Prostacyclin Generation by the Vessel Wall. Journal of Clinical Investigation. 63:1026-1035. 1979
- Experience with an Albumin‐Enhanced, 15‐Minute Incubation, Emergency Crossmatch. Transfusion. 19:95-97. 1979
- Platelet Transfusion‐Induced Serratia Marcescens Sepsis due to Vacuum Tube Contamination. Transfusion. 19:39-44. 1979
- Characterization of human malignant melanoma cell lines. III. Membrane immunofluorescence reactivity with sera from patients with melanoma. Cancer Immunology, Immunotherapy. 3:239-246. 1978
- HLA-A,B,C and B-lymphocyte alloantigens in insulin-dependent diabetes.. Transplantation Proceedings. 9:1859-1861. 1977
- Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 117:33-36. 1977
- A Complement independent erythropoietic inhibitor acting on the progenitor cell in refractory anemia. American Journal of Medicine. 61:572-578. 1976
- Inhibition of Injury Induced Thromboatherosclerotic Lesions by Anti-Platelet Serum in Rabbits. Thrombosis and Haemostasis. 35:070-081. 1976
- Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy. British Journal of Cancer. 32:323-330. 1975
- Anomalous ABO Grouping Due to a New Serum Factor Reactive with a Reagent Coloring Material. Transfusion. 13:150-152. 1973